Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Autor: Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E.
Přispěvatelé: Conte P., Frassoldati A., Bisagni G., Brandes A.A., Donadio M., Garrone O., Piacentini F., Cavanna L., Giotta F., Aieta M., Gebbia V., Molino A., Musolino A., Ferro A., Maltoni R., Danese S., Zamagni C., Rimanti A., Cagossi K., Russo A., Pronzato P., Giovanardi F., Moretti G., Lombardo L., Schirone A., Beano A., Amaducci L., Bajardi E.A., Vicini R., Balduzzi S., D'Amico R., Guarneri V.
Rok vydání: 2018
Předmět:
Oncology
Time Factors
Adjuvant
Breast cancer
Cardiac safety
De-escalated treatment
Trastuzumab
Settore MED/06 - Oncologia Medica
Receptor
ErbB-2
medicine.medical_treatment
Anthracycline
030204 cardiovascular system & hematology
Breast cancer
Antineoplastic Agents
Immunological
ErbB-2
0302 clinical medicine
Trastuzumab
Antineoplastic Combined Chemotherapy Protocols
Clinical endpoint
Anthracyclines
skin and connective tissue diseases
Adjuvant
Mastectomy
Cardiac safety
De-escalated treatment
Hazard ratio
Hematology
Middle Aged
Chemotherapy regimen
Bridged-Ring Compound
Immunological
Local
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
Taxoids
Trastuzumab
adjuvant
breast cancer
cardiac safety
de-escalated treatment
Breast Neoplasm
Human
Receptor
medicine.drug
Adult
Bridged-Ring Compounds
medicine.medical_specialty
Time Factor
Socio-culturale
Breast Neoplasms
Antineoplastic Agents
Disease-Free Survival
Drug Administration Schedule
03 medical and health sciences
Taxoid
Internal medicine
medicine
Humans
Chemotherapy
Risk factor
Aged
Neoplasm Staging
Antineoplastic Combined Chemotherapy Protocol
business.industry
medicine.disease
Cardiotoxicity
Neoplasm Recurrence
Neoplasm Recurrence
Local
business
Zdroj: Annals of Oncology. 29:2328-2333
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy414
Popis: Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)
Databáze: OpenAIRE
Externí odkaz: